Abstract | CONTEXT: OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial of 17 patients with Marfan syndrome (mean [SD], 33 [6] years) taking standard beta-blocker therapy, initiated in January 2004 and completed in September 2006, at Alfred Hospital Marfan Syndrome Clinic, Melbourne, Australia. INTERVENTION: Patients were administered 8 mg/d of perindopril (n = 10) or placebo (n = 7) for 24 weeks. MAIN OUTCOME MEASURES: Indices of arterial stiffness were assessed via systemic arterial compliance, and central and peripheral pulse wave velocities. Aortic root diameters were assessed at 4 sites via transthoracic echocardiography. RESULTS:
Perindopril reduced arterial stiffness as indicated by increased systemic arterial compliance (mean [SEM], 0.33 [0.01] mL/mm Hg at baseline to 0.54 [0.04] mL/mm Hg at 24 weeks in perindopril group vs 0.30 [0.01] mL/mm Hg to 0.29 [0.01] mL/mm Hg in placebo group, P = .004), and reduced central (7.6 [0.4] m/s to 5.9 [0.3] m/s in perindopril group, P < .001 vs placebo) and peripheral (10.9 [0.4] m/s to 8.7 [0.4] m/s in perindopril group, P < .001 vs placebo) pulse wave velocities. In addition, perindopril significantly reduced aortic root diameters relative to placebo in both end-systole and end-diastole (P<.01 to P < .001 for all comparisons between groups). Although perindopril marginally reduced mean arterial pressure (from 81 [2] mm Hg to 80 [1] mm Hg in perindopril group vs 83 [2] mm Hg to 84 [3] mm Hg in placebo group, P = .004), the observed changes in both stiffness and left ventricular outflow tract diameter remained significant when mean arterial pressure was included as a covariate. Transforming growth factor beta ( TGF-beta), which contributes to aortic degeneration in Marfan syndrome, was reduced by perindopril compared with placebo in both latent (59 [6] ng/mL to 45 [3] ng/mL in perindopril group, P = .01 vs placebo) and active (46 [2] ng/mL to 42 [1] ng/mL in perindopril group, P = .02 vs placebo) forms. CONCLUSIONS: TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00485368.
|
Authors | Anna A Ahimastos, Anuradha Aggarwal, Kellie M D'Orsa, Melissa F Formosa, Anthony J White, Ravi Savarirayan, Anthony M Dart, Bronwyn A Kingwell |
Journal | JAMA
(JAMA)
Vol. 298
Issue 13
Pg. 1539-47
(Oct 03 2007)
ISSN: 1538-3598 [Electronic] United States |
PMID | 17911499
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Retracted Publication)
|
Chemical References |
- Adrenergic beta-Antagonists
- Angiotensin-Converting Enzyme Inhibitors
- Transforming Growth Factor beta
- Angiotensin II
- Matrix Metalloproteinase 3
- Matrix Metalloproteinase 2
- Perindopril
|
Topics |
- Adrenergic beta-Antagonists
(therapeutic use)
- Adult
- Angiotensin II
(antagonists & inhibitors)
- Angiotensin-Converting Enzyme Inhibitors
(pharmacology, therapeutic use)
- Aorta
(diagnostic imaging, drug effects, pathology)
- Arteries
(diagnostic imaging, drug effects, physiology)
- Blood Flow Velocity
- Blood Pressure
- Double-Blind Method
- Echocardiography
- Female
- Humans
- Male
- Marfan Syndrome
(diagnostic imaging, drug therapy, physiopathology)
- Matrix Metalloproteinase 2
(blood)
- Matrix Metalloproteinase 3
(blood)
- Perindopril
(pharmacology, therapeutic use)
- Transforming Growth Factor beta
(blood)
- Ultrasonography, Doppler
- Vasodilation
(drug effects)
|